TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cell Stem Cell

• Publication date

  2010-12-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.stem.2010.11.014PMID 21112565
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.

  2010cited by this paper
• Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells

  2010cited by this paper
• CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.

  2010cited by this paper
• PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2

  2010cited by this paper
• CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

  2009cited by this paper
• Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation.

  2009cited by this paper
• CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

  2009cited by this paper
• Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.

  2009cited by this paper
• FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.

  2009cited by this paper
• Non‐obese diabetic–recombination activating gene‐1 (NOD–Rag 1 null) interleukin (IL)‐2 receptor common gamma chain (IL 2 rγnull) null mice: a radioresistant model for human lymphohaematopoietic engraftment

  2008cited by this paper
• Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats

  2008cited by this paper
• Differential Effects of the Type I Interferons α4, β, and ε on Antiviral Activity and Vaccine Efficacy1

  2008cited by this paper
• Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.

  2008cited by this paper
• Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells

  2007cited by this paper
• Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region

  2007cited by this paper
• CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia

  2007cited by this paper
• Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells

  2007cited by this paper
• Antibodies, Fc receptors and cancer.

  2007cited by this paper
• TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells.

  2007cited by this paper
• Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells

  2007cited by this paper
• Right on target: eradicating leukemic stem cells.

  2007cited by this paper
• Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.

  2006cited by this paper
• Targeting of CD44 eradicates human acute myeloid leukemic stem cells

  2006cited by this paper
• Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignancies

  2006cited by this paper
• The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.

  2005cited by this paper
• Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia.

  2005cited by this paper
• Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice.

  2005cited by this paper
• Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding

  2005cited by this paper
• Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice

  2005cited by this paper
• Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

  2004cited by this paper
• The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

  2004cited by this paper
• Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance

  2003cited by this paper
• Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance

  2003cited by this paper
• Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

  2002cited by this paper
• Prospective isolation of human clonogenic common myeloid progenitors

  2002cited by this paper
• High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*

  2001cited by this paper
• Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice.

  1997cited by this paper
• Rapid amplification of cDNA ends (RACE) improves the PCR-based isolation of immunoglobulin variable region genes from murine and human lymphoma cells and cell lines

  1997cited by this paper
• Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

  1997cited by this paper
• A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

  1994cited by this paper
• Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice

  1993cited by this paper

• Inside the Battle Against Acute Myeloid Leukemia: Biology, Breakthroughs, and Hope.

  2026cites this paper
• Pre-therapeutic bone marrow-resident leukemic cells in acute myeloid leukemia exhibit a distinct dysregulated calcium signature and stem-like profile reflecting minimal residual disease precursors

  2026cites this paper
• Targeting T cell exhaustion in colorectal cancer: emerging roles of LAG-3, TIM-3, and TIGIT signaling in overcoming immunotherapy resistance

  2026cites this paper
• HPCAL1 as a novel prognostic biomarker in acute myeloid leukemia and its correlation with immune infiltrates

  2025cites this paper
• Preclinical targeting of leukemia-initiating cells in the development future biologics for acute myeloid leukemia

  2025cites this paper
• KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML

  2025cites this paper
• NAP1L5 in acute myeloid leukemia: a prognostic biomarker and potential therapeutic target

  2025cites this paper
• Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival

  2025cites this paper
• A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias

  2025cites this paper
• Circular RNAs in cancer stem cells: Insights into their roles and mechanisms (Review)

  2025cites this paper
• Distinct leukemogenic mechanism of acute promyelocytic leukemia based on genomic structure of PML::RARα

  2025cites this paper
• TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives

  2025cites this paper
• Resolving leukemic stem cell heterogeneity and plasticity with single-cell multiomics.

  2025cites this paper
• Comparison the impact of IFN-β alone or in combination with vitamin D on critical pathways involved in AML progression

  2025cites this paper
• Towards Canine Immunotherapy Models: Monoclonal Antibodies with Redox Regulated Epitopes Targeting TIM3 Attenuate Galectin-9 Binding.

  2025cites this paper
• Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target

  2025cites this paper
• The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy

  2025cites this paper
• Role of immune checkpoint inhibitors in breast cancer and hematological malignancies

  2025cites this paper
• Immune checkpoint inhibitor (ICI) therapy in central nervous system cancers: State-of-the-art and future outlook.

  2025cites this paper
• Immune checkpoints regulate acute myeloid leukemia stem cells

  2025influential citation
• Recent advances of CAR-T cells in acute myeloid leukemia

  2025cites this paper
• Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting

  2025cites this paper
• The role of telomeres in leukemic stem cells function

  2025cites this paper
• Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

  2025cites this paper
• Is There a Future for CAR-T Therapy in Acute Myeloid Leukemia?

  2025cites this paper
• CAR-NK cells for haematological cancers.

  2025cites this paper
• Unveiling the potential of CLL-1: a promising target for AML therapy

  2025cites this paper
• Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T‐cell therapy

  2025cites this paper
• Precision medicine with car cells in acute myeloid leukemia: where are we?

  2025cites this paper
• Regulating Ferroptosis in Leukemic Stem Cells: From Stemness Preservation to Targeted Differentiation Strategies

  2025cites this paper
• Emerging Insights into TIM-3: A Potential Immune Checkpoint for Lung Cancer Immunotherapeutic Strategies

  2025cites this paper
• Targeting glycosylation to enhance tumor immunotherapy.

  2025cites this paper
• TIM-3 Promotes Proliferation of Acute Myeloid Leukemia Blasts

  2025cites this paper
• Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti–TIM-3 therapy in mice

  2024cites this paper
• The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View

  2024cites this paper
• β-Catenin in Dendritic Cells Negatively Regulates CD8 T Cell Immune Responses through the Immune Checkpoint Molecule Tim-3

  2024cites this paper
• Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells

  2024cites this paper
• Galectin-9, a pro-survival factor inducing immunosuppression, leukemic cell transformation and expansion

  2024cites this paper
• Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia

  2024cites this paper
• Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models

  2024cites this paper
• Anti-TIM3 chimeric antigen receptor-natural killer cells preferentially target primitive acute myeloid leukemia cells with minimal fratricide and exhaustion

  2024cites this paper
• Immunophenotypic characterization of leukemic stem cells in acute myeloid leukemia using single tube 10‐colour panel by multiparametric flow cytometry: Deciphering the spectrum, complexity and immunophenotypic heterogeneity

  2024cites this paper
• Establishment of novel anti-TIM-3 antibodies interfering with its binding to ligands

  2024cites this paper
• Evaluating targeted therapies in older patients with TP53-mutated AML

  2024influential citation
• The Functional Role and Prognostic Significance of TIM-3 Expression on NK Cells in the Diagnostic Bone Marrows in Acute Myeloid Leukemia

  2024cites this paper
• TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells

  2024cites this paper
• Novel Peptide-Based 68Ga-Labeled Radiotracer for Preclinical Studies of TIM3 Expression.

  2024cites this paper
• LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.

  2024cites this paper
• TIM-3/Galectin-9 interaction and glutamine metabolism in AML cell lines, HL-60 and THP-1

  2024cites this paper
• Development of a preclinical model of myeloid tumors with high immune checkpoints expression

  2024cites this paper
• The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation

  2024cites this paper
• TIM‐3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation

  2024influential citation
• Naturally selected CD7-directed CAR-T bridging allo-HSCT in refractory acute myeloid leukemia: a case report and review

  2024cites this paper
• Beyond T cell exhaustion: TIM-3 regulation of myeloid cells

  2024cites this paper
• Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy.

  2024cites this paper
• Features and prognostic significance of soluble TIM-3 and its ligands Gal-9 and CEACAM1 levels in the diagnostic bone marrows of adult acute myeloid leukemia patients.

  2024cites this paper
• Integrin-α9 overexpression underlies the niche-independent maintenance of leukemia stem cells in acute myeloid leukemia.

  2024cites this paper
• Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML

  2024cites this paper
• The dark side of stemness – the role of hematopoietic stem cells in development of blood malignancies

  2024cites this paper
• Immunophenotypic features of early haematopoietic and leukaemia stem cells

  2024cites this paper
• Immunotherapeutic targeting of surfaceome heterogeneity in AML.

  2024cites this paper
• The expression of Galectin‐9 correlates with mTOR and AMPK in murine colony‐forming erythroid progenitors

  2024cites this paper
• Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy

  2024cites this paper
• Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells.

  2024cites this paper
• Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting

  2023cites this paper
• The Therapeutic Potential of a Strategy to Prevent Acute Myeloid Leukemia Stem Cell Reprogramming in Older Patients

  2023cites this paper
• Sabatolimab (MBG453) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors

  2023cites this paper
• An Overview of Targeted Therapies in Acute Myeloid Leukemia

  2023cites this paper
• Checkpoint Inhibitors in Acute Myeloid Leukemia

  2023cites this paper
• Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells.

  2023cites this paper
• Therapeutic targeting of leukemia stem cells in acute myeloid leukemia

  2023cites this paper
• Emerging role of interactions between tumor angiogenesis and cancer stem cells.

  2023cites this paper
• Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents

  2023cites this paper
• Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?

  2023cites this paper
• Cancer Stem Cells are Actually Stem Cells with Disordered Differentiation: the Monophyletic Origin of Cancer

  2023cites this paper
• Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells

  2023cites this paper
• Galectins dysregulation: A way for cancer cells to invade and pervade

  2023cites this paper
• TIM-3 signaling hijacks the canonical Wnt/β-catenin pathway to maintain cancer stemness in acute myeloid leukemia

  2023cites this paper
• Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.

  2023cites this paper
• Flow cytometric analysis of CD34+CD38− cells; cell frequency and immunophenotype based on CD45RA expression pattern

  2023cites this paper
• TGF-β, EMT, and resistance to anti-cancer treatment.

  2023cites this paper
• Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia

  2023cites this paper
• Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment

  2023cites this paper
• Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease

  2023cites this paper
• PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia

  2023cites this paper
• Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy

  2023cites this paper
• Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress

  2023cites this paper
• Immunotherapy in Acute Myeloid Leukemia: A Literature Review of Emerging Strategies

  2023cites this paper
• TIM-3/Gal-9 interaction affects glucose and lipid metabolism in acute myeloid leukemia cell lines

  2023cites this paper
• Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

  2023cites this paper
• Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?

  2023cites this paper
• Cardiac glycoside ouabain efficiently targets leukemic stem cell apoptotic machinery independent of cell differentiation status

  2023cites this paper
• An overview of novel therapies in advanced clinical testing for acute myeloid leukemia

  2023cites this paper
• Molecular Mechanisms in Murine Syngeneic Leukemia Stem Cells

  2023cites this paper
• Non-genetic mechanisms of drug resistance in acute leukemias.

  2023cites this paper
• Checkpoint inhibition in hematologic malignancies

  2023cites this paper
• [Pathophysiology of myelodysplastic syndromes].

  2023cites this paper
• A guide to epigenetics in leukaemia stem cells

  2023cites this paper
• Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

  2023influential citation
• Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature

  2023cites this paper